Influenza

Tivic Health Announces Launch of New and Improved ClearUP 2.0

Retrieved on: 
Monday, January 8, 2024
General Health, Medical Devices, Other Health, Health, Health Technology, Influenza, Common, Allergy, Cheek, FDA, Congestion, Patient, Nose, Pressure, System, Life

Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP.
  • The new and improved Tivic ClearUP 2.0, now with a new chip for power management for faster charge and longer battery life, is available starting today on TivicHealth.com.
  • ClearUP 2.0 is a clinically proven way to clear congestion and relieve sinus pain.
  • It is an FDA-approved, 100% drug-free and non-addictive way to reduce sinus pain, pressure, sinus headaches, and congestion due to colds, flu, and allergies.

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Tetra, Medical Subject Headings, Marketing, Influenza, Protein, Influenza vaccine, Immune system, World, Fatigue, Hydrocortisone, H3N2, Virus, ATC, Antibody, Pain, WHO, Influenza A virus, International, Vaccine, Headache, Disease, Ageing, Language, Ovalbumin, Influenza B virus, Formaldehyde, European Medicines Agency, Neomycin, World Health Organization, Select, Patient, Time, Anatomy, IIA

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Tetra, Medical Subject Headings, Marketing, Protein, INN, Immune system, Risk, Fatigue, World, H3N2, Allergy, ATC, Pain, WHO, International, Vaccine, Headache, Disease, Ageing, Language, Influenza, Tenderness, Irritability, Influenza B virus, H1N1, European Medicines Agency, World Health Organization, Select, Patient, Bruise, Safety, Anatomy, IIA, Skin

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Supemtek, Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 4, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Influenza, Protein, INN, Immune system, World, ATC, Pain, WHO, International, Vaccine, Disease, Language, Vaccination, Influenza A virus, Tenderness, European Medicines Agency, World Health Organization, Select, Patient, Safety, Anatomy, Influenza B virus, IIA

Human medicines European public assessment report (EPAR): Supemtek, Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Supemtek, Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 4, Status: Authorised

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Retrieved on: 
Wednesday, November 29, 2023
Cocrystal, Lung, Doctor of Philosophy, COCP, Viral, Oseltamivir, Influenza, Vaccine

In his presentation, “Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344,” Cocrystal President and co-CEO Sam Lee, PhD discussed the potential prevention and therapy of influenza infection using inhaled CC-42344.

Key Points: 
  • In his presentation, “Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344,” Cocrystal President and co-CEO Sam Lee, PhD discussed the potential prevention and therapy of influenza infection using inhaled CC-42344.
  • Dr. Lee commented that CC-42344 exhibits superior antiviral activity compared with oseltamivir (Tamiflu®) and demonstrates a novel mechanism of action with high barrier of resistance.
  • “We are excited to accomplish another important milestone with the influenza antiviral CC-42344.
  • “Inhaled CC-42344 could be developed for both therapeutic and prophylactic influenza treatment.

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Viral, Protease, Research, Safety, Disease, MERS, Gastroenteritis, CFO, Influenza, COCP, Death, FDA, Vaccine, Merck, G&A, Pharmacokinetics, COVID-19, Therapy, CDC, RNA, R, SARS-CoV-2, Cocrystal, A, SARS, Enzyme, Pharmaceutical industry, Cryptocurrency, Medical device, Norovirus

Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.

Key Points: 
  • Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.
  • Research and development (R&D) expenses for the third quarter of 2023 were $4.2 million, compared with $3.9 million for the third quarter of 2022.
  • Cocrystal reported unrestricted cash as of September 30, 2023 of $29.7 million, compared with $37.1 million as of December 31, 2022.
  • The Company had working capital of $30.3 million and 10.2 million common shares outstanding as of September 30, 2023.

Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Health, Pharmaceutical, Viral, Pfizer, Research, RSV, Market, Combination, Pneumonia, Incidence, Ageing, Urinary tract infection, Investment, Risk, Traction, Vaccination, Respiratory disease, FDA, Vaccine, USD, Influenza, COVID-19, Infection, Growth, SARS-CoV-2, Pharmaceutical industry

The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease vaccine market size is expected to reach USD 70.30 billion by 2030, expanding at a CAGR of 1.21% from 2023 to 2030
    The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology.
  • Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.
  • In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2.

Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836

Retrieved on: 
Tuesday, December 5, 2023
Research, Other Health, Pharmaceutical, White House, Federal Government, Infectious Diseases, Other Manufacturing, Clinical Trials, Science, Biotechnology, Health, Public Policy, Government, Other Science, Manufacturing, NIAID, Safety, Sustainable energy, Entrepreneurship, Principal investigator, Risk, Innovation, Vaccine, USD, Infection, NIH, Human, CEA, Influenza, Public

The grant (project number 1R01AI177376) will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.

Key Points: 
  • The grant (project number 1R01AI177376) will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.
  • The IDMIT is highly specialized in human infectious diseases and has the facilities needed for testing the immunogenicity and efficacy of OVX836 as a vaccine against pandemic influenza strains in preclinical models.
  • “Receiving this grant from the NIAID will support our progress in developing OVX836 to provide broad-spectrum protection against influenza, which remains a perennial pandemic threat,” commented Alexandre Le Vert, Co-Founder and CEO of Osivax.
  • Osivax also recently published the results of a Phase 2a dose-optimization study ( OVX836-003 ) in The Lancet Infectious Diseases showing efficacy in humans against seasonal strains.

Global Seasonal Influenza Vaccine Research Report 2023: Trivalent vs. Quadrivalent, Injection vs. Nasal Spray - Market Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Infectious Diseases, Pharmaceutical, Health, World Health Organization, Inactivation, Research, Distribution, Market, Pediatrics, Healthcare Facilities Accreditation Program, Porter W. Anderson Jr., WHO, Hospital, Vaccination, Weather, Death, SWOT, Vaccine, USD, Influenza, Fatality, Porter's five forces analysis, Country, Government, Anthrax Vaccine Immunization Program, Research report, Retail, Pharmacy

The Global Seasonal Influenza Vaccine Market is poised to reach USD 9.3 Billion by 2029, a significant increase from the 2022 figure of USD 5.8 Billion.

Key Points: 
  • The Global Seasonal Influenza Vaccine Market is poised to reach USD 9.3 Billion by 2029, a significant increase from the 2022 figure of USD 5.8 Billion.
  • Over the forecast period from 2024 to 2029, the Global Seasonal Influenza Vaccines market is anticipated to grow at a steady CAGR of 7.61%.
  • Several factors contribute to the favorable growth of the Global Seasonal Influenza Vaccine market.
  • The report presents the analysis of Seasonal Influenza Vaccine Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029
    The report analyses the Seasonal Influenza Vaccine Market by Valency (Quadrivalent, Trivalent)
    The report analyses the Seasonal Influenza Vaccine Market by Age Group (Pediatrics, Adults, Elderly)
    The report analyses the Seasonal Influenza Vaccine Market by Distribution Channel (Hospitals, Pharmacies, Government Supply)
    The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.

Major new vaccines initiative aims to fight deadly airborne infections

Retrieved on: 
Monday, December 18, 2023
Novo Nordisk Foundation, SSI, Research, Senior, Nasal spray, Disease, Statens Serum Institut, History, Faculty, University of Copenhagen, Immunology, Death, Vaccine, Science, GAS, Influenza, Medicine, University, Infection, Human, Partnership, DKK, Interior, Streptococcus, COVID-19 vaccine, Respiratory system, Microbiology, COVID-19, Knowledge, Life, Tuberculosis, Public, TB, Pharmaceutical industry, Management, Immunity, NIVI, Health

The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.

Key Points: 
  • The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.
  • Developed in partnership with the University of Copenhagen, it is the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
  • "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen.
  • "We hope that NIVI's work can help prepare us for the next pandemic or even help consign airborne epidemics to history."